Autoimmune diseases are a diverse group of more than 80 described conditions characterized by abnormal immune reactivity which affect hundreds of millions of people around the world and are the third leading cause of mortality in the industrial world after cancer and heart disease. For reasons that are not clear, the prevalence of autoimmune diseases is generally rising throughout the world.

The most common autoimmune diseases include Rheumatoid Arthritis, Systemic Lupus erythematosus (SLE), multiple sclerosis (MS) and type 1 diabetes mellitus (T1DM) all of which are major health concerns. The first line of treatment for autoimmunity is steroids, which cause severe side effects including neuropsychological, dermal and metabolic disorders. When severe side effects rise the treatment is changed to biologics, which are very expensive and complicated to administer.

There is a need for better and safer anti-inflammatory treatments.

AimVion answers this need by developing a new class of anti-inflammatory peptides derived from human genetic elements towards clinical use as a treatment for autoimmunity.